Pfizer Inc.

Pfizer Inc.

PFENYSE / NASDAQHealthcareLarge cap

$27.40-$0.14 (-0.5%)

Last close · Data as of Nov 20, 2026

Market cap
$146.4B
P/E
18.8x
EV / EBITDA
12.5x
Revenue
$62.6B
Net margin
12.4%
ROCE
9.2%

+12.3% over the last year

Pfizer Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-9.0%
3M
-1.4%
6M
+6.2%
1Y
+12.3%
5Y
-46.1%

52-week range

Day change -$0.14 (-0.5%) from $27.54 to $27.40 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PFE, bought on each weekday since 2021.

News & filings

What Pfizer filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernNet profit fell 37.2% a year over three years.

Strengths (1)

  • Operating margin of 25.2% against a peer median of 19.6%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.

Read moreShow less

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector
Healthcare
Shares outstanding
5.67B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$146.4B
P/E
18.8x
P/B
1.7x
EV / EBITDA
12.5x
EV / Sales
3.3x
P/S
2.3x
52-week high
$30.79
52-week low
$23.67

Profitability

Operating margin
25.2%
Net margin
12.4%
EBITDA margin
26.8%
ROE
9.0%
ROCE
9.2%
ROA
3.7%
Asset turnover
0.30

Growth

Revenue
$62.6B
Revenue growth, 1Y
-1.6%
Revenue CAGR, 3Y
-14.8%
Net profit growth, 1Y
-3.2%
Free cash flow
$9.1B

Solvency

Current ratio
1.16
Debt / Equity
0.74
Debt / Assets
0.31
CFO / Net profit
1.51
Cash / Market cap
0.8%

Where the revenue went

Of every $100 of FY2025 revenue, $12 was left as net income.

Pfizer Inc. income statement flow, FY2025
Pfizer Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$16.1B
RevenueGross profit$46.5B
Gross profitResearch and development$12.1B
Gross profitSelling, general and administrative$13.8B
Gross profitOther operating expenses$4.9B
Gross profitOperating income$15.8B
Operating incomePretax income$7.5B
Operating incomeInterest and other expense$8.3B
Pretax incomeNet income$7.5B
Tax benefit and otherNet income$251.0M

Revenue and net profit

Revenue fell 1.6% in FY2025; net profit is the dashed line.

Pfizer Inc. revenue and net profit by fiscal year
Pfizer Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$101.2B$31.4B
FY2023$59.6B$2.1B
FY2024$63.6B$8.0B
FY2025$62.6B$7.8B

Cash flows

FY2025: $11.7B from operations, $9.1B free after investment (dashed).

Pfizer Inc. operating and free cash flow by fiscal year
Pfizer Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$29.3B$26.0B
FY2023$8.7B$4.8B
FY2024$12.7B$9.8B
FY2025$11.7B$9.1B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$62.6B-1.6%1Y
EBITDA
$16.8B-7.4%1Y
Net profit
$7.8B-3.2%1Y
Cash from operations
$11.7B-8.2%1Y
Free cash flow
$9.1B-7.7%1Y
Revenue CAGR, 3Y
-14.8%
Net profit CAGR, 3Y
-37.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$62.6B$16.8B$7.8B$9.1B9.0%-1.6%-3.2%

Monthly returns

Month-by-month returns of PFE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$208.2B
Liabilities$121.4B
Equity$86.8B
Paid-in capital$94.5B
Retained earnings$114.6B
Treasury stock$115.0B
Minority interest$299.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PFE highlighted.

P/E against peers

PFE trades at 18.8x earnings against a peer median of 31.1x (a 40% discount).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Pfizer Inc.PFEthis companyP/E ↓ discount$146.4B18.8x1.7x9.0%12.5x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Stryker CorporationSYK$115.5B35.6x5.2x14.5%20.2x
Peer median—31.1x4.3x13.5%18.8x

Year-to-date ROI

PFE since 1 January, against earlier years.

Historical volatility

PFE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Pfizer Inc. operating margin by fiscal year
Pfizer Inc. operating margin by fiscal year
DateOperating margin
FY202236.7%
FY20237.1%
FY202423.3%
FY202525.2%
LineFY2025
Cost of revenueCost Of Revenue$16.1B
Gross profitGross Profit$46.5B
Operating expensesOperating Expense$30.7B
Research and developmentResearch And Development$12.1B
Selling, general and administrativeSelling General And Administration$13.8B
Depreciation and amortisationDepreciation And Amortization In Income Statement$4.9B
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$4.9B
Amortization$4.9B
Amortisation of intangiblesAmortization Of Intangibles Income Statement$4.9B
Total expensesTotal Expenses$46.8B
Operating incomeOperating Income$15.8B
Pretax incomePretax Income$7.5B

Learn while you research

Academy chapters picked for Pfizer Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →